Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases

Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals

(2020) Lawrence Drudge-Coates et al.   SUPPORTIVE CARE IN CANCER

Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration

(2019) AnneMarthe Mjelstad et al.   SUPPORTIVE CARE IN CANCER

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline

(2019) Noam Yarom et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study

(2019) Ana Laura Soares et al.   SUPPORTIVE CARE IN CANCER

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

(2018) Noopur Raje et al.   LANCET ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention

(2018) Adepitan A. Owosho et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw

(2018) Tomoko Higuchi et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study

(2018) Aline Guillot et al.   Clinical Genitourinary Cancer

Extensive Surgical Procedures Result in Better Treatment Outcomes for Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Osteoporosis

(2017) Hui Young Kim et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients

(2016) Leena Vehmanen et al.   ACTA ONCOLOGICA

Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw

(2016) Toshiyuki Yoneda et al.   JOURNAL OF BONE AND MINERAL METABOLISM

OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice

(2015) Rafael Scaf de Molon et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

(2014) Aliya A Khan et al.   JOURNAL OF BONE AND MINERAL RESEARCH

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

(2014) Salvatore L. Ruggiero et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Bisphosphonate Use and the Risk of Adverse Jaw Outcomes

(2014) Vassiliki M. Cartsos et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

(2011) F. Saad et al.   ANNALS OF ONCOLOGY

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

(2011) Tim Van den Wyngaert et al.   SUPPORTIVE CARE IN CANCER

Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound

(2010) Jonathan R. Green et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases

(2010) M. Aapro et al.   ONCOLOGIST

Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw

(2009) Konstantinos Vahtsevanos et al.   JOURNAL OF CLINICAL ONCOLOGY

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan

(2008) C. I. Ripamonti et al.   ANNALS OF ONCOLOGY

“Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw

(2008) Mario H. ABU-ID et al.   JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY